Ishiyama D, Kanai Y, Senda H, Iwatani W, Iwatani W, Konno H, Kanazawa S
Metabolism Research, Kaken Pharmaceutical Co., Ltd., Fujieda, Shizuoka, Japan.
J Antibiot (Tokyo). 2000 Sep;53(9):873-8. doi: 10.7164/antibiotics.53.873.
The structures of novel topoisomerase I inhibitors, topopyrones A, B, C and D were elucidated by spectral analysis of the chemical derivatives. These compounds are an anthraquinone type containing a fused 1,4-pyrone moiety. Topopyrones A and B contain a chlorine atom, however C and D do not. It was suggested that topopyrones B and D are converted from topopyrones A and C, respectively by Wessely-Moser type rearrangement.
通过对化学衍生物的光谱分析阐明了新型拓扑异构酶I抑制剂拓扑吡喃A、B、C和D的结构。这些化合物是含有稠合1,4-吡喃部分的蒽醌类型。拓扑吡喃A和B含有一个氯原子，然而C和D则没有。有人提出，拓扑吡喃B和D分别是由拓扑吡喃A和C通过韦塞利-莫泽型重排转化而来的。
